chronic hepatitis B comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-04. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Coagulation factor VIII (factor VIII, FVIII, also known as antihemophilic factor A (AHF)) is an essential blood clotting protein. In humans, it is encoded by F8 gene. Defects in this gene result in hemophilia A, an X-linked bleeding disorder. Factor VIII is produced in the liver's sinusoidal cells and endothelial cells outside the liver throughout the body. This protein circulates in the bloodstream in an inactive form, bound to a plasma carrier (another protein) called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein (sometimes written as coagulation factor VIIIa) interacts (by an as-yet-unknown mechanism) with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot. Factor VIII participates in blood coagulation; it is a cofactor for factor IXa, which, in the presence of Ca2+ and phospholipids, forms a complex that converts factor X to the activated form Xa. The factor VIII gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity.
== External links == IamGSD — International Association for Muscle Glycogen Storage Disease Walking With McArdle's — IamGSD videos EUROMAC Introduction — Video about McArdle disease and the EUROMAC Registry of McArdle disease and other rare glycogenoses patients
== Geography == Yavne is a city in the Central District of Israel, located about six kilometers from the Mediterranean Sea in the southern coastal plain region, on the eastern border of the Yavne sand dunes. It is situated between the moshav of Ben Zakai to the south, Ashdod, Gan Yavne, Hazor Ashdod, and Nitzanim to the southwest, Gan Raveh and Kfar HaNagid to the north, Givat Brenner to the east, Bait Gamliel to the southeast, Rehovot to the east-southeast, and Gealya to the northeast.
Includes the perirhinal and entorhinal cortices. Rhombencephalon Also known as the hindbrain, this embryonic brain region gives rise to the pons, medulla oblongata, and cerebellum. Ribosome A cellular organelle responsible for protein synthesis. In neurons, local ribosome activity occurs in dendrites and axons, supporting synaptic plasticity. Rostral A directional term meaning “toward the nose” or front of the brain. Often used in anatomical descriptions of the central nervous system. Ruffini ending A slow-adapting mechanoreceptor found in the skin that detects skin stretch and contributes to proprioception and object manipulation. RUNX1 A transcription factor involved in sensory neuron differentiation and pain signaling. Active during embryonic development and in peripheral nervous system patterning.
== Terminology == The term "usual" refers to the fact that UIP is the most common form of interstitial fibrosis. "Pneumonia" indicates "lung abnormality", which includes fibrosis and inflammation. A term previously used for UIP in the British literature is cryptogenic fibrosing alveolitis (CFA), a term that has fallen out of favor since the basic underlying pathology is now thought to be fibrosis, not inflammation. The term usual interstitial pneumonitis (UIP) has also often been used, but again, the -itis part of that name may overemphasize inflammation.
Sources: en.wikipedia.org
Within two years, they had opened 29 stores in Singapore and Malaysia, almost as many stores as the Hymans had opened in their 35 years of ownership. In 1998, the Sassoons, along with longtime friend Severin Wunderman, purchased the parent company, International Coffee & Tea LLC, from the Hymans, and took it global. Victor Sassoon worked out of Singapore, Sunny Sassoon worked in Los Angeles, and Wunderman was a silent partner with no role in management. International Coffee & Tea, LLC remained the name of the holding company. Sunny Sassoon served as president and CEO from 1998 until 2009, when he moved to the executive chairman position until 2019. In 2009, Mel Elias (Sassoon's brother-in-law) assumed the role of president and CEO of the company, after spending seven years as chief operating officer. In September 2013, a significant equity position in Coffee Bean was acquired from International Coffee & Tea by US-based Advent International, in partnership with South Korea-based Mirae Asset Private Equity and Taiwan-based CDIB Capital. The Sassoon family remains a large shareholder. John Fuller served as president and CEO from 2015 to 2020. In April 28, 2014, Hyman died at the age of 82. He had heart disease. In 2019, the Philippines' Jollibee Foods Corporation (JFC) acquired The Coffee Bean & Tea Leaf for $350 million, making it Jollibee's biggest investment at the time. JFC bought it through Java Ventures LLC, a company from the US that is a wholly owned subsidiary of Super Magnificent Coffee Company Pte. Ltd. in Singapore, a subsidiary of Jollibee Worldwide Pte Ltd.
These events caused widespread devastation, and even depopulated the north, resulting in the complete social and political breakdown and collapse of central authority in the Central Plains, triggering massive, sustained waves of Han Chinese migration into South China, leading to the formation of distinct Han lineages, who also likely assimilated the by-now partially sinicized Bai Yue in their midst. Modern Han Chinese subgroups, such as the Cantonese, the Hakka, the Henghua, the Hainanese, the Hoklo peoples, the Gan, the Xiang, the Wu-speaking peoples, all claim Han Chinese ancestry pointing to official histories and their own genealogical records to support such claims. Linguists hypothesize that proto- Wu and Min varieties of Chinese may have originated from the time of Jin, while the proto- Yue and Hakka varieties perhaps from the Tang and Song, about half-a-millennium later. The presence of Tai-Kradai substrates in these dialects may have been due to the assimilation of the remaining groups of Bai Yue, integrating these lands into the Sinosphere proper.
Naturally occurring silver (47Ag) is composed of the two stable isotopes 107Ag and 109Ag in almost equal proportions, with 107Ag being slightly more abundant (51.839% natural abundance). Notably, silver is the only element with multiple NMR-active isotopes all having spin 1/2. Thus both 107Ag and 109Ag nuclei produce narrow lines in nuclear magnetic resonance spectra. 40 radioisotopes have been characterized with the most stable being 105Ag with a half-life of 41.29 days, 111Ag with a half-life of 7.43 days, and 112Ag with a half-life of 3.13 hours. All of the remaining radioactive isotopes have half-lives that are less than an hour, and the majority of these have half-lives that are less than 3 minutes. This element has numerous meta states, with the most stable being 108mAg (half-life 439 years), 110mAg (half-life 249.86 days) and 106mAg (half-life 8.28 days). Known isotopes of silver range in atomic weight from 92Ag to 132Ag. The primary decay mode before the most abundant stable isotope, 107Ag, is electron capture and the primary mode after is beta decay. The primary decay products before 107Ag are palladium (element 46) isotopes and the primary products after are cadmium (element 48) isotopes. The palladium isotope 107Pd decays by beta emission to 107Ag with a half-life of 6.5 million years. Iron meteorites are the only objects with a high enough palladium/silver ratio to yield measurable variations in 107Ag abundance. Radiogenic 107Ag was first discovered in the Santa Clara meteorite in 1978.
=== Hierarchical structure === While the secondary structures are determined by energy state and hydrogen bonds formed between amino acids, hierarchical structures are determined by the hydrophobicity of the peptide. Exon 1 encoded peptide is mainly hydrophilic, and is more extended when immersed in water. In contrast, exon 3 encoded peptide contains both hydrophobic and hydrophilic blocks, suggesting the formation of micelles, where the hydrophobic block will cluster on the inside with the hydrophilic portion surrounding it. Thus, a single complete resilin protein, when immersed in water, takes on the structure in which exon 1 encoded segment extends out from the micelle exon 3 encoded peptide forms. Once resilin is transferred to the outside of the cell, their exon 2 encoded peptides, the chitin binding segments, bind to chitin. Meanwhile, di- or tri-tyrosine crosslinking is formed by oxidative coupling, mediated by peroxidase, between tyrosine residuals. Like other elastomeric proteins, the degree of cross linking in resilin is low, which ensures the low stiffness and high resilience. Cross linked peptides encoded by exon 1 have a resilience greater than 93%, while that encoded by exon 3 has a resilience of 86%. In addition, natural resilin has a resilience of 92%, similar to that of exon 1, suggesting again that exon 1 may play a more important role in the elastic property of resilin.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.